Molecular Insight Pharmaceuticals, Inc. To Present at BIO CEO & Investor Conference
February 06 2008 - 8:30AM
Business Wire
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced
today that David S. Barlow, Chairman and Chief Executive Officer of
Molecular Insight Pharmaceuticals, Inc., will present on two
occasions at the 10th Annual BIO CEO & Investor Conference at
the Waldorf=Astoria Hotel in New York, New York. On February 11,
2008, Mr. Barlow will participate in an opening plenary panel
called, �Check Your Options: Raising Public and Private Financing
in Today�s Marketplace�, where he will offer his expert insight on
the current life sciences financing climate. On February 12, 2008,
Mr. Barlow will present an overview of Molecular Insight and its
pipeline of molecular radiotherapeutic and molecular imaging
pharmaceutical candidates. Opening Plenary Panel �Check Your
Options: Raising Public and Private Financing in Today�s
Marketplace, Part II� Monday, February 11, 2008 4:15 pm - 5:30 pm
Eastern Time Jade Room Molecular Insight Pharmaceuticals, Inc.
Company Presentation Tuesday, February 12, 2008 9:30 am - 10:10 am
Eastern Time Louis XVI Center The Molecular Insight company
presentation will be webcast live at
www.corporate-ir.net/ireye/conflobby.zhtml?ticker=MIPI&item_id=1752407
and will be archived for one year. It will also be available in the
Investor Relations section of the Molecular Insight Pharmaceuticals
website at www.molecularinsight.com. About Molecular Insight
Pharmaceuticals, Inc. Molecular Insight Pharmaceuticals (NASDAQ:
MIPI) is a biopharmaceutical company specializing in the emerging
field of molecular medicine, applying innovations in the
identification and targeting of disease at the molecular level to
improve healthcare for patients with life-threatening diseases. The
company is focused on discovering, developing and commercializing
innovative, molecular radiotherapeutics and molecular imaging
pharmaceuticals with initial applications in the areas of oncology
and cardiology. Its lead molecular radiotherapeutic product
candidates, Azedra and Onalta, are being developed for detection
and treatment of cancer. The company�s lead molecular imaging
pharmaceutical product candidate, Zemiva, is being developed for
the diagnosis of cardiac ischemia, or insufficient blood flow to
the heart. In addition, the company has a growing pipeline of
product candidates resulting from application of its proprietary
platform technologies to new and existing compounds. Molecular
Insight Pharmaceuticals is based in Cambridge, Massachusetts and
its website address is: www.molecularinsight.com. Forward-Looking
Statements Statements in this release that are not strictly
historical in nature constitute "forward-looking statements." Such
statements include, but are not limited to, statements about the
development of Azedra�, Onalta �, Zemiva� and our other product
candidates. Such forward-looking statements involve known and
unknown risks, uncertainties, and other factors that may cause the
actual results of Molecular Insight to be materially different from
historical results or from any results expressed or implied by such
forward-looking statements. These factors include, but are not
limited to, risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval for product candidates; competition from other
pharmaceutical or biotechnology companies; and the additional risks
discussed in filings with the Securities and Exchange Commission.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and Molecular Insight undertakes no
obligation to revise or update this news release to reflect events
or circumstances after the date hereof.
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From Jul 2023 to Jul 2024